Bayer buys Algeta

Share this article:

Bayer is ponying up $2.9 billion to buy now-former oncology partner Algeta, reports PMLive. The deal means Bayer will own the prostate cancer therapy Xofigo outright.

The company previously estimated the alpha-particle-emitting therapeutic agent would hit $1.3 billion in annual sales.

The FDA approved the treatment in May.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.